| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
60,180 |
55,110 |
$5.51M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
46,067 |
42,783 |
$2.95M |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
18,947 |
17,948 |
$1.04M |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
7,556 |
7,075 |
$555K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
6,517 |
6,254 |
$260K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
2,127 |
2,112 |
$216K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
1,281 |
1,280 |
$179K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
1,898 |
1,896 |
$174K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
6,962 |
6,508 |
$165K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
7,968 |
4,634 |
$157K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
6,095 |
5,797 |
$120K |
| 80050 |
General health panel |
2,644 |
2,638 |
$82K |
| 36415 |
Collection of venous blood by venipuncture |
11,227 |
10,561 |
$44K |
| 80061 |
Lipid panel |
3,699 |
3,690 |
$44K |
| 96127 |
|
8,594 |
8,222 |
$43K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
925 |
553 |
$42K |
| 80053 |
Comprehensive metabolic panel |
3,817 |
3,777 |
$36K |
| 99215 |
Prolong outpt/office vis |
197 |
181 |
$31K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
468 |
468 |
$30K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
3,630 |
3,589 |
$25K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
2,506 |
2,498 |
$22K |
| 99406 |
|
1,605 |
1,546 |
$22K |
| G0483 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed |
93 |
93 |
$20K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
213 |
213 |
$20K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
1,122 |
1,113 |
$20K |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
182 |
182 |
$19K |
| 99442 |
|
262 |
258 |
$19K |
| 82670 |
|
739 |
733 |
$18K |
| 96367 |
|
834 |
509 |
$17K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
589 |
586 |
$17K |
| 99396 |
Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years |
149 |
148 |
$16K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
148 |
148 |
$13K |
| 84410 |
|
276 |
266 |
$13K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
256 |
250 |
$12K |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
82 |
79 |
$11K |
| 84439 |
|
1,294 |
1,285 |
$10K |
| 84443 |
Thyroid stimulating hormone (TSH) |
685 |
683 |
$10K |
| 84153 |
|
595 |
588 |
$10K |
| 99490 |
Ccm add 20min |
1,451 |
1,448 |
$10K |
| 84403 |
|
411 |
384 |
$10K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
91 |
91 |
$9K |
| 84270 |
|
442 |
425 |
$9K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
96 |
96 |
$8K |
| 90472 |
Immunization administration, each additional vaccine (list separately) |
269 |
267 |
$8K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
568 |
566 |
$8K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
313 |
312 |
$8K |
| 99443 |
|
78 |
78 |
$8K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
394 |
243 |
$7K |
| J1071 |
Injection, testosterone cypionate, 1 mg |
3,027 |
1,581 |
$7K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
71 |
66 |
$6K |
| 87653 |
|
165 |
164 |
$6K |
| 87641 |
|
162 |
161 |
$6K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
159 |
158 |
$5K |
| 96368 |
|
341 |
229 |
$5K |
| 82627 |
|
223 |
221 |
$4K |
| 83001 |
|
262 |
260 |
$4K |
| 87481 |
|
128 |
127 |
$4K |
| 82728 |
|
314 |
312 |
$4K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
121 |
121 |
$4K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
102 |
101 |
$4K |
| 87640 |
|
99 |
98 |
$4K |
| 87500 |
|
98 |
97 |
$3K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
109 |
109 |
$3K |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
109 |
109 |
$3K |
| 87511 |
|
109 |
109 |
$3K |
| 84146 |
|
196 |
194 |
$3K |
| 99439 |
|
478 |
478 |
$3K |
| 99441 |
|
67 |
66 |
$3K |
| 87581 |
|
85 |
85 |
$3K |
| 87541 |
|
85 |
85 |
$3K |
| 87556 |
|
81 |
81 |
$3K |
| 87561 |
|
81 |
81 |
$3K |
| 87529 |
|
44 |
44 |
$3K |
| 87486 |
|
73 |
73 |
$3K |
| 84480 |
|
202 |
201 |
$3K |
| 93922 |
|
48 |
48 |
$2K |
| J3475 |
Injection, magnesium sulfate, per 500 mg |
919 |
553 |
$2K |
| 84144 |
|
109 |
109 |
$2K |
| 82533 |
|
112 |
111 |
$2K |
| 99385 |
|
14 |
14 |
$2K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
459 |
280 |
$2K |
| 84402 |
|
64 |
64 |
$1K |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
592 |
354 |
$1K |
| 96366 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour |
84 |
54 |
$1K |
| 95927 |
|
19 |
19 |
$1K |
| 83002 |
|
56 |
55 |
$954.60 |
| 82607 |
|
72 |
72 |
$949.69 |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
26 |
12 |
$793.37 |
| 81025 |
|
81 |
80 |
$618.06 |
| G2058 |
Chronic care management services, each additional 20 minutes of clinical staff time directed by a physician or other qualified health care professional, per calendar month (list separately in addition to code for primary procedure). (do not report g2058 for care management services of less than 20 minutes additional to the first 20 minutes of chronic care management services during a calendar month). (use g2058 in conjunction with 99490). (do not report 99490, g2058 in the same calendar month as 99487, 99489, 99491)). |
104 |
104 |
$529.04 |
| 87274 |
|
48 |
48 |
$511.68 |
| 87273 |
|
48 |
48 |
$511.68 |
| 99051 |
|
76 |
76 |
$499.24 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
603 |
392 |
$494.96 |
| 84481 |
|
28 |
28 |
$421.96 |
| 84436 |
|
60 |
59 |
$371.59 |
| 87503 |
|
12 |
12 |
$297.00 |
| 99173 |
|
111 |
111 |
$280.34 |
| J7042 |
5% dextrose/normal saline (500 ml = 1 unit) |
131 |
77 |
$140.11 |
| 93000 |
|
12 |
12 |
$127.46 |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
45 |
45 |
$125.96 |
| J1040 |
Injection, methylprednisolone acetate, 80 mg |
13 |
13 |
$116.63 |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
14 |
12 |
$86.79 |
| 96160 |
|
1,864 |
1,841 |
$80.59 |
| G0506 |
Comprehensive assessment of and care planning for patients requiring chronic care management services (list separately in addition to primary monthly care management service) |
13 |
13 |
$63.15 |
| J3420 |
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg |
233 |
120 |
$51.60 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
146 |
86 |
$46.67 |
| 90715 |
|
17 |
17 |
$0.00 |
| G0444 |
Annual depression screening, 5 to 15 minutes |
45 |
45 |
$0.00 |
| 90651 |
|
15 |
15 |
$0.00 |
| 90686 |
|
50 |
50 |
$0.00 |